Is enlicitide FDA-approved, and what does the research show?

What is enlicitide?

Enlicitide is a prescription medicine that lowers LDL cholesterol, low-density lipoprotein cholesterol, in adults ¹. It is not a wellness, weight or performance peptide: its completed phase 3 trials measured cholesterol in adults with high cholesterol ², ⁵, ⁸. FDA's label describes it as "a macrocyclic peptide that binds to PCSK9," a protein that acts in the liver ¹. A macrocyclic peptide is a short chain of amino acids closed into a ring.

Merck developed it under the code name MK-0616 and sells it in the United States as Lipfendra ³, ⁹, ⁸. The tablet contains enlicitide decanoate, a salt of the peptide, with a molecular weight of 1,722 ¹. The company's statement calls it "the first FDA-approved oral PCSK9 inhibitor," Merck's words ⁹.

Is enlicitide FDA-approved?

Yes. Enlicitide is approved by FDA as the prescription medicine Lipfendra, with initial U.S. approval in 2026 ¹⁰, ¹. FDA's Drugs@FDA record shows Merck's new drug application, NDA 220848, approved on July 15, 2026, as a tablet with marketing status "Prescription" ³. FDA reviewed it as a new molecular entity, a drug it had not approved before, on a priority review ³, ⁴.

The label approves it "as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)" ¹⁰, ¹. Hypercholesterolemia means high cholesterol in the blood; heterozygous familial hypercholesterolemia is an inherited form, carried on one copy of a gene. That is the label's one use. It lists no indication for weight, for wellness, or for people without high cholesterol ¹.

The label adds a sentence about heart risk, in its own words: "Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy" ¹. Those trials were of statins and of the injected antibodies, not of enlicitide ¹. Enlicitide's own heart outcomes trial is still running ¹¹. A licensed clinician's prescription is the only route to it ¹. FDA did not refer the application to an advisory committee, its panel of outside experts, because the safety data "did not raise significant safety or efficacy issues that were unexpected for a drug of this class" ⁴.

See the FDA status of every peptide, updated weekly.

How does enlicitide work?

PCSK9 is a protein that binds to LDL receptors on the surface of liver cells and marks them for destruction ¹. Fewer receptors means less LDL cholesterol is pulled out of the blood ¹. Enlicitide binds to PCSK9 and stops it from binding to the receptor, so, in the label's words, it "increases the number of LDLRs available to clear LDL-C, thereby lowering LDL-C levels" ¹. This is the same target the antibody drugs evolocumab and alirocumab hit ¹, ⁶, ⁷.

The tablet includes sodium caprate, an absorption aid, which the label says "facilitates the oral absorption of enlicitide" ¹. Even so, about 1 percent of a dose is absorbed, and taking it after a meal roughly halves the amount that reaches the blood ¹.

What does the research show?

FDA approved enlicitide on two randomized, placebo-controlled phase 3 trials, so its evidence level is "Approved for a use" ¹, ², ⁵. A phase 3 trial is the large, late-stage trial run before approval; placebo-controlled means some participants took an identical tablet with no drug in it. Both trials enrolled adults whose LDL cholesterol stayed high while they were taking a statin, unless they could not tolerate one ¹. The sponsor of every trial below was Merck, which the papers name as MSD ², ⁵, ⁸.

Studied in people against placebo: CORALreef Lipids, published February 4, 2026, randomized 2,909 adults at 168 sites in 14 countries ². Some had a past heart attack, stroke or similar event, with an LDL of 55 mg/dL or higher ². The rest were at increased risk of a first such event, with an LDL of 70 or higher ². The mean age was 63, 39 percent were women, and the mean LDL at the start was 96 mg/dL ². Of the 2,904 treated, 1,935 took enlicitide and 969 took placebo for 52 weeks ², ¹.

At 24 weeks, LDL cholesterol fell by 57.1 percent on enlicitide and rose by 3.0 percent on placebo ². The adjusted difference was 55.8 percentage points, with a 95 percent confidence interval of 50.7 to 60.9 ². At 52 weeks the fall was 50.4 percent against a rise of 4.0, a difference of 47.6 points ¹². At 24 weeks, non-HDL cholesterol and apolipoprotein B, two other measures of cholesterol-carrying particles, fell by 54 and 50 percent on enlicitide against rises of 3 on placebo ¹. At 24 weeks, 70.3 percent on enlicitide reached an LDL below 70 mg/dL with at least a 50 percent reduction, against 1.5 percent on placebo ¹².

Studied in people with the inherited form: CORALreef HeFH, published online November 9, 2025, randomized 303 adults at 59 sites in 17 countries ⁵. All were on a statin, 82 percent at high intensity, and 64 percent also took ezetimibe, another cholesterol pill ⁵. The mean age was 52, half were women, and the mean LDL at the start was 119 mg/dL ⁵.

In the 202 on enlicitide, LDL fell by 58.2 percent at 24 weeks; in the 101 on placebo it rose by 2.6 ⁵. The difference was 59.4 points, with a 95 percent confidence interval of 53.2 to 65.6 ⁵. At 52 weeks the fall was 55.3 percent against a rise of 8.7, a difference of 61.5 points ⁵.

Head to head with two other cholesterol pills: CORALreef AddOn, published online March 30, 2026, randomized 301 adults on statins for 56 days ⁸. It compared enlicitide with ezetimibe, with bempedoic acid, a newer cholesterol pill, and with the two together, in arms of 101, 50, 50 and 100 ⁸. LDL fell by 64.6 percent on enlicitide, 27.8 on ezetimibe, 6.3 on bempedoic acid and 36.5 on the pair ⁸. Enlicitide beat each comparator ⁸.

Before these, a phase 2 trial published online March 6, 2023 had randomized 381 adults with high cholesterol to four strengths or placebo for 8 weeks ¹³. LDL fell by 41 to 61 percent more than on placebo, depending on the strength ¹³.

No trial has yet reported whether enlicitide prevents heart attacks, strokes or deaths ², ¹¹. CORALreef Outcomes, a placebo-controlled trial with an estimated 14,550 participants, began in October 2023 and is expected to finish collecting its main result in November 2029 ¹¹. Merck says the trial "has completed enrollment with over 14,500 participants" and that "it is not yet known if LIPFENDRA can reduce the risk of cardiovascular morbidity and mortality," the company's words ⁹. The large trial's authors wrote that it "was not powered to detect rare adverse events," meaning too small to find them ².

No completed efficacy trial of enlicitide for any purpose other than lowering cholesterol is among the sources cited here as of November 10, 2026 ², ⁵, ⁸, ¹³, ¹¹. Every phase 3 trial above enrolled adults with high cholesterol, nearly all on statins, and the cholesterol changes reported are those seen in that population ², ⁵, ⁸.

What are the side effects?

In the large trial, side effects were about as common on enlicitide as on placebo. Over 52 weeks of treatment and 8 weeks of follow-up, 64.3 percent of the 1,935 on enlicitide reported an adverse event, against 62.1 percent of the 969 on placebo ². Serious adverse events occurred in 9.9 percent against 12.0 ². Stopping because of an adverse event was 3.1 percent against 4.1, and 13 people died on enlicitide and 7 on placebo, 0.7 percent in each group ². New or worsening diabetes was recorded in 6.1 percent against 5.8, and no case of drug-induced liver injury occurred in either group ².

The most common events in that trial were infections of the nose and throat, upper airway infections and COVID-19, each in 2 to 5 percent of either group ². Headache, high blood pressure, diarrhea, back pain and urinary infections were each reported by about 2.5 percent on enlicitide, close to placebo ². In the inherited-form trial, the label names the two reactions more common than placebo: "diarrhea (LIPFENDRA 7%, placebo 2%) and dizziness (LIPFENDRA 9%, placebo 4%)" ¹. In that trial, 9 of 202 on enlicitide and 4 of 101 on placebo had a serious adverse event, and one person on enlicitide died, none on placebo ¹⁴. In the 56-day head-to-head trial, no one on enlicitide had a serious adverse event, against five of the 200 on the comparators ¹⁵.

FDA's label carries no boxed warning, FDA's strongest warning, and no warnings and precautions section, and under "Contraindications" it says "None" ¹. On pregnancy, it says: "Discontinue LIPFENDRA when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus," because lowering cholesterol "may cause fetal harm" by the drug's mechanism ¹. It says there is no information on the drug in human milk, and that safety and effectiveness "have not been established in pediatric patients" ¹. Of 2,137 people treated in the placebo-controlled trials, 960 were 65 or older, and the label found no overall difference in safety or effect by age ¹. The label reports no clinically meaningful drug interactions in its studies, which included levothyroxine, warfarin, atorvastatin and oral semaglutide ¹.

In sport

Enlicitide is not named on WADA's 2026 Prohibited List, and PCSK9 inhibitors are not a listed class ¹⁶. WADA, the World Anti-Doping Agency, lists hormone and metabolic modulators in section S4, but no term for cholesterol or lipids appears anywhere on it ¹⁶.

What JumpstartMD offers

JumpstartMD does not prescribe enlicitide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.